Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva
08. Januar 2024 02:00 ET
|
Essential Pharma
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Colobreathe® is an inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in...